Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

Completed · Phase 2

Conditions studied: Heart Failure, Congestive, Renal Insufficiency

In brief

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Key facts

Study ID

NCT00159614

Run by

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

People needed

30

Starts

2005-09-01

Last updated by the study team

2008-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stable congestive heart failure
• Impaired renal function
• Taking oral loop diuretic

You may not qualify if…

• Acutely decompensated (unstable) and end stage heart failure
• Diuretics other than loop diuretics
• Pregnant or nursing
• Inability to follow instructions
• Participation in another clinical trial within past 30 days

Where it is running

• Study site — San Diego, California, United States
• Study site — Baltimore, Maryland, United States
• Study site — Ayer, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Kalamazoo, Michigan, United States
• Study site — Tullahoma, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.